Company: FVN
Filing Date: 2025-04-14
Form Type: DRS/A
Source: 0001829126-25-002616
Chunk: 79

Company: Future Vision II Acquisition Corp.
Filing Date: 2025-04-14
Form: DRS/A
Chunk 79
---
 do not publish research or publish inaccurate or unfavorable research about New VIWO or its business, its ordinary shares price and trading volume could decline. |

| ● | If New VIWO cannot satisfy, or continue to satisfy, the initial listing requirements and other rules of Nasdaq, New VIWO’s securities may not be listed or may be delisted, which could negatively impact the price of its securities and your ability to sell them. |

| ● | You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because New VIWO is incorporated under Cayman Islands law. |

| ● | You may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in China against New VIWO or its management named in the proxy statement based on foreign laws. |

| ● | Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect New VIWO’s business, investments and results of operations. |

| ● | Future changes to tax laws could adversely affect New VIWO. |

| ● | New VIWO is an emerging growth company within the meaning of the Securities Act, and if New VIWO takes advantage of certain exemptions from disclosure requirements available to emerging growth companies, this could make New VIWO’s securities less attractive to investors and may make it more difficult to compare New VIWO’s performance with other public companies. |

| ● | As a foreign private issuer, we are not subject to certain U.S. securities law disclosure requirements that apply to a domestic U.S. issuer, which may limit the information publicly available to New VIWO’s shareholders. |

| ● | As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from the Nasdaq listing standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with corporate governance listing standards. |

<div align='center'>40</div>

Risks Related to New VIWO’s ordinary shares and Organizational Structure

| ● | The price of New VIWO’s ordinary shares likely will be volatile like the shares of other early-stage companies. |

| ● | If the Business Combination’s benefits do not meet the expectations of investors or securities analysts, the market price of our securities may decline. |

| ● | If securities or industry analysts do not publish research or publish unfavorable research about our business, our share price and trading volume could decline. |

| ● | We may fail to realize